Center-Authored Papers

Filters: Author is Jones, Robin L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL.  2013.  Clinical benefit of trabectedin in uterine adenosarcoma.. Medical oncology (Northwood, London, England). 30(2):501. Abstract
Schroeder B, Pollack SM, Jones RL.  2014.  Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth.. Gynecologic oncology. 132(2):513.
Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Tos APD, Raspagliesi F, Judson I, Casali PG.  2011.  Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.. Gynecologic oncology. 123(3):553-6. Abstract
R
Rajendra R, Pollack SM, Jones RL.  2013.  Management of gastrointestinal stromal tumors.. Future oncology (London, England). 9(2):193-206. Abstract
Rajendra R, Jones RL, Pollack SM.  2013.  Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib.. OncoTargets and therapy. 6:217-22. Abstract
Rainey D, Berriochoa J, Korpak A, Zeng J, Loggers ET, Jones RL, Patel S.  2016.  Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years.. Journal of radiation oncology. 5:169-177. Abstract
P
Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL.  2017.  Novel therapeutic approaches in chondrosarcoma.. Future oncology (London, England). 13(7):637-648. Abstract
Pollack SM, Pillarisetty VG, Padia SA, Jones RL.  2013.  The use of radiofrequency ablation in gastrointestinal stromal tumor.. Journal of vascular and interventional radiology : JVIR. 24(5):751.
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M et al..  2014.  Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.. Journal for immunotherapy of cancer. 2(1):36. Abstract
Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B et al..  2017.  T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.. Cancer. Abstract
Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.. PloS one. 7(2):e32165. Abstract
Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL.  2011.  Immune-based therapies for sarcoma.. Sarcoma. 2011:438940. Abstract
Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.. Cancer. 118(18):4564-70. Abstract
Petek BJ, Loggers ET, Pollack SM, Jones RL.  2015.  Trabectedin in soft tissue sarcomas.. Marine drugs. 13(2):974-83. Abstract
O
Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR.  2011.  Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations.. Sarcoma. 2011:402508. Abstract
N
Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL.  2014.  The multidisciplinary management of giant cell tumor of bone.. Expert review of anticancer therapy. 14(7):783-90. Abstract
Newman EN, Jones RL, Hawkins DS.  2012.  An evaluation of [F-18]-fluorodeoxy-D-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma.. Pediatric blood & cancer. Abstract
M
Meyer JM, Perlewitz KS, Hayden JB, Doung Y-C, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A et al..  2013.  Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Mazbani E, Jones RL, Fink J, Chamberlain MC.  2013.  Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma.. Journal of neuro-oncology. Abstract
L
Lee ATJ, Huang PH, Pollack SM, Jones RL.  2016.  Drug repositioning in sarcomas and other rare tumors.. EBioMedicine. 6:4-5.
Lee ATJ, Pollack SM, Huang P, Jones RL.  2017.  Phase III Soft Tissue Sarcoma Trials: Success or Failure? Current treatment options in oncology. 18(3):19. Abstract
J
Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, Hoch BL.  2014.  Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.. Human pathology. 45(8):1563-71. Abstract
Jones RL, Constantinidou A.  2012.  The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma.. International journal of clinical oncology / Japan Society of Clinical Oncology.
Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP.  2013.  A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.. Investigational new drugs. Abstract
Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart CA, O'Bryant C, Moore KN.  2015.  A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.. Cancer chemotherapy and pharmacology. Abstract